Purification and activity assay of HSA-AX15 (R13K) fusion protein expressed in Pichia pastoris / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 254-258, 2005.
Artículo
en Chino
| WPRIM
| ID: wpr-249915
ABSTRACT
To increase the in vivo half-life of human CNTF mutein AX15 (R13K), HSA-AX15 (R13K) fusion protein was constructed by the fusion of the C-terminus of HSA to the N-terminus of AX15 (R13K) via an 11 amino acids linker. HSA-AX15 (R13K) fusion protein was purified to homogeneity by cation exchange chromatography, reverse phase chromatography and gel filtration after expressed in pichia pastoris. TF-1 cell survival bioassay showed the biological activity of AX15 (R13K) was not affected by the fusion to HSA. It was demonstrated that tertian injection of 4.8 mg/kg HSA-AX15 (R13K) fusion protein could produce more potent anti-obesity effects on KM mice than daily injection of 1.6 mg/kg AX15 (R13K). The long-acting form of hCNTF variant has the potential to reduce discomfort by requiring fewer injections and to minimize the side-effects by decreasing the dosage and fluctuation of plasma concentration, and thus has superior clinical application.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pichia
/
Proteínas Recombinantes de Fusión
/
Albúmina Sérica
/
Factor Neurotrófico Ciliar
/
Proteínas Mutantes
/
Genética
/
Metabolismo
Límite:
Animales
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Biotechnology
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS